Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

Breast Cancer Research and Treatment

Volumn 136, Issue 3, 2012, Pages 673-682

  Gökmen Polar, Yesim ^a   Liu, Yi ^b   Toroni, Rachel A ^a   Sanders, Kerry L ^a   Mehta, Rutika ^a   Badve, Sunil ^a   Rommel, Christian ^b   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Intellikine LLC   (United States)

Author keywords

Breast cancer; mTOR; PIK3CA; TORC1 2 inhibitor; Vascular endothelial growth factor

Indexed keywords

B RAF KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MLN 0128; MYC PROTEIN; PROTEIN KINASE B; PROTEIN NDRG1; PROTEIN S6; RAPAMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOXAZOLE DERIVATIVE; BRAF PROTEIN, HUMAN; INK128; MTORC1 COMPLEX, HUMAN; MULTIPROTEIN COMPLEX; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PROTEIN; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRAF GENE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MITOSIS INHIBITION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; BLOOD; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; FEMALE; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MULTIPROTEIN COMPLEXES; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878759479     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2298-8     Document Type: Article

References (48)

1. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22
2. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278-2287
3. Laplante M, Sabatini DM (2009) An emerging role of mTOR in lipid biosynthesis. Curr Biol 19:R1046-R1052
4. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497-5510
5. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562
6. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091
7. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M (2007) Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5:195-201
8. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189-3199
9. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, et al. (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782-1788
10. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101
11. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-1128
12. Abraham RT, Eng CH (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 12:209-222
13. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508
14. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8
15. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7:e38
16. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421:29-42
17. Feldman ME, Shokat KM (2010) New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of tor kinase domain inhibitors (TORKinibs). Curr Top Microbiol Immunol 347:241-262
18. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70:288-298
19. Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, et al. (2011) Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 10:1394-1406
20. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023-8032
21. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55-61
22. McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J (1998) Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 153:1993-2006
23. Gokmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, et al. (2010) Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat 124:3227-3235
24. Gokmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, et al. (2011) Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res Treat 127:375-384
25. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
26. Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, Roman Y, et al. (2005) The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 4:1004-1012
27. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66:41-45
28. Muggerud AA, Edgren H, Wolf M, Kleivi K, Dejeux E, Tost J, et al. (2009) Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. BMC Med Genomics 2:26
29. Lee DF, Hung MC (2007) All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 6:3011-3014
30. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ (2002) Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16:771-780
31. Vinals F, Chambard JC, Pouyssegur J (1999) p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem 274:26776-26782
32. Yu Y, Sato JD (1999) MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 178:235-246
33. Qu Z, Van Ginkel S, Roy AM, Westbrook L, Nasrin M, Maxuitenko Y, et al. (2008) Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res 68:6232-62340
34. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932-1940
35. Wander SA, Hennessy BT, Slingerland JM (2011) Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121:1231-1241
36. Vilar E, Perez-Garcia J, Tabernero J (2011) Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10:395-403
37. Garcia-Echeverria C (2010) Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 20:4308-4312
38. Dales JP, Garcia S, Bonnier P, Duffaud F, Carpentier S, Djemli A, et al. (2003) Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol 23:297-305
39. Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1):37-44
40. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van GME, Geurts-Moespot A, et al. (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414
41. Finkenzeller G, Weindel K, Zimmermann W, Westin G, Marme D (2004) Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp1. Angiogenesis 7:59-68
42. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, et al. (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10:1706-1716
43. Linderholm B, Andersson J, Lindh B, Beckman L, Erlanson M, Edin K, et al. (2004) Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer 40:33-42
44. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, et al. (2004) Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 123:1151-1161
45. Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC, et al. (2005) ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24:4370-4379
46. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Harris AL (1998) Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 77:2120-2128
47. Mina LA, Sledge GW Jr (2011) Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol 8:325-332
48. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15:1612-1622